Johnson & Johnson [NYSE: JNJ] gained 0.13% or 0.22 points to close at $163.61 with a heavy trading volume of 4564243 shares. The company report on March 29, 2021 that Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Task Team for the Company’s COVID-19 Vaccine Candidate.
Up to 400 million doses of the Company’s single-shot vaccine candidate will be made available to African Union member states.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Availability of the vaccine is subject to national regulatory approvals.
It opened the trading session at $163.55, the shares rose to $164.28 and dropped to $163.316, the range by which the price of stock traded the whole day. The daily chart for JNJ points out that the company has recorded 10.38% gains over the past six months. However, it is still -22.42% lower than its most recent low trading price.
If we look at the average trading volume of 8.15M shares, JNJ reached to a volume of 4564243 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Johnson & Johnson [JNJ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $185.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 28, 2020. While these analysts kept the previous recommendation, BofA/Merrill raised their target price from $150 to $175. The new note on the price target was released on April 22, 2020, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $163, while Citigroup analysts kept a Buy rating on JNJ stock.
The Average True Range (ATR) for Johnson & Johnson is set at 2.34, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 5.26. The Price to Book ratio for the last quarter was 6.81, with the Price to Cash per share for the same quarter was set at 9.48. Price to Free Cash Flow for JNJ in the course of the last twelve months was 44.78 with Quick ratio for the last quarter at 1.00.
Trading performance analysis for JNJ stock
Johnson & Johnson [JNJ] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.85. With this latest performance, JNJ shares gained by 3.95% in over the last four-week period, additionally plugging by 10.38% over the last 6 months – not to mention a rise of 17.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 56.11, with the RSI for the last a single of trading hit 57.41, and the three-weeks RSI is set at 55.07 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 162.32, while it was recorded at 163.52 for the last single week of trading, and 152.11 for the last 200 days.
Johnson & Johnson [JNJ]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +24.79 and a Gross Margin at +66.09. Johnson & Johnson’s Net Margin is presently recorded at +17.82.
Return on Total Capital for JNJ is now 21.80, given the latest momentum, and Return on Invested Capital for the company is 16.02. Return on Equity for this stock inclined to 23.97, with Return on Assets sitting at 8.85. When it comes to the capital structure of this company, Johnson & Johnson [JNJ] has a Total Debt to Total Equity ratio set at 57.47. Additionally, JNJ Total Debt to Total Capital is recorded at 36.50, with Total Debt to Total Assets ending up at 20.79. Long-Term Debt to Equity for the company is recorded at 53.31, with the Long-Term Debt to Total Capital now at 33.86.
Reflecting on the efficiency of the workforce at the company, Johnson & Johnson [JNJ] managed to generate an average of $109,398 per employee. Receivables Turnover for the company is 5.89 with a Total Asset Turnover recorded at a value of 0.50.Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
Johnson & Johnson [JNJ]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Johnson & Johnson posted 2.3/share EPS, while the average EPS was predicted by analysts to be reported at 1.99/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 5.61%.
An analysis of insider ownership at Johnson & Johnson [JNJ]
There are presently around $295,295 million, or 69.90% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 227,946,104, which is approximately -0.454% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 188,510,542 shares of the stock with an approximate value of $30.84 billion in JNJ stocks shares; and STATE STREET CORP, currently with $23.56 billion in JNJ stock with ownership of nearly -3.829% of the company’s market capitalization.
Positions in Johnson & Johnson stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,799 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 58,093,871 shares. Additionally, 1,228 investors decreased positions by around 58,030,302 shares, while 267 investors held positions by with 1,688,749,038 shares. The mentioned changes placed institutional holdings at 1,804,873,211 shares, according to the latest SEC report filing. JNJ stock had 337 new institutional investments in for a total of 13,553,875 shares, while 61 institutional investors sold positions of 2,478,765 shares during the same period.